產(chǎn)品名稱 |
EL 1 |
商品貨號(hào) |
B164402 |
Organism |
Homo sapiens, human |
Tissue |
spleen |
Product Format |
frozen |
Morphology |
monocyte/macrophage |
Culture Properties |
suspension |
Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
Derivation |
The EL 1 cell line was established from cryopreserved human spleen cells. |
Comments |
The cells tend to grow as single cells but may form small nonadherent clusters. |
Complete Growth Medium |
Iscove's modified Dulbecco's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate and supplemented with 0.05 mM 2-mercaptoethanol, 0.1 mM hypoxanthine and 0.016 mM thymidine, 90%; calf serum, 10%
|
Subculturing |
Medium Renewal: Every 2 to 3 days (or as necessary to maintain the cell concentration between 2 X 10 exp5 and 1 X 10 exp6 cells/ml) Cultures can be maintained by addition or replacement of fresh medium. Maintain the cell concentration between 2 X 10 exp5 and 1 X 10 exp6 cells/ml. |
Cryopreservation |
culture medium 95%; DMSO, 5% |
Culture Conditions |
Temperature: 37.0°C |
STR Profile |
This cell line was originally deposited in support of a patent (US Patent 5,447,861).
STR profiling at ATCC indicates similarity to other cell lines including:
U-937 (ATCC CRL-1593.2) and
SC (ATCC CRL-9855) |
Name of Depositor |
E.I. du Pont de Nemours & Co. |
Deposited As |
Homo sapiens |
U.S. Patent Number |
|
References |
Collins GW, Largen MT. Continuous mammalian cell lines having monocyte/macrophage characteristics and their establishment in vitro. US Patent 5,447,861 dated Sep 5 1995
|